Gerresheimer Faces Critical Deadline Amid Deepening Accounting Crisis

German packaging firm Gerresheimer faces a severe crisis with major asset impairments, dual BaFin investigations into accounting, and a crucial March 2026 deadline for its audited statements.

The German packaging specialist Gerresheimer finds itself navigating its most severe corporate crisis in recent memory. A combination of substantial asset impairments, a plummeting share price, and serious internal accounting irregularities has severely shaken investor confidence. The situation now hinges on a crucial deadline: March 31, 2026, by which the company must deliver its audited annual financial statements. Failure to meet this date risks a significant escalation of its troubles.

Internal Failures Trigger Regulatory Scrutiny

At the heart of the turmoil are admitted violations of internal guidelines and accounting rules by certain employees. These breaches, which primarily concern revenue recognition and the valuation and accounting of inventory, have forced the company to initiate corrective measures. Gerresheimer has engaged a second auditing firm to investigate the full scope of the issues.

The financial repercussions are severe. For 2025, the company anticipates impairment charges ranging from €220 million to €240 million, though these are stated to have no cash flow impact. Key drivers are write-downs at its Sensile Medical unit in Switzerland and the Gerresheimer Moulded Glass Chicago operation in the United States. Consequently, the adjusted EBITDA margin is now projected to be just 16.5% to 17.5%, down from a prior forecast of 18.5% to 19.0%. Adjusted earnings per share are expected to fall by a high double-digit percentage, with a net loss becoming a distinct possibility.

Twin BaFin Probes Increase Pressure

Germany's Federal Financial Supervisory Authority (BaFin) has significantly tightened the screws. Its initial probe, launched in September 2025 into potential accounting violations, was expanded in late February. The regulator is now conducting two parallel investigations: one into the 2024 consolidated financial statements and another into the 2025 half-year financial report.

The 2024 audit focuses on €65.5 million in leasing liabilities and €29.4 million in capitalized development costs that may have been reported incorrectly. For the 2025 interim report, BaFin has identified three core problem areas: an outdated risk reporting system, omitted impairment charges, and improperly recorded revenues from bill-and-hold agreements.

Asset Sale and Legal Threats Emerge

In a bid to shore up its balance sheet, Gerresheimer plans to sell its US subsidiary Centor within 2026, a process to be guided by investment bank Morgan Stanley. Centor manufactures packaging systems for prescription drugs and operates in a high-margin segment. However, the company has abandoned previously announced plans to divest its Moulded Glass business.

As some institutional investors, like the CastleKnight Master Fund which reported a 4.08% stake in early March, move in, legal challenges are forming. The Deutsche Schutzvereinigung für Wertpapierbesitz (DSW), a German shareholder association, has announced it will examine potential claims for damages against members of the executive and supervisory boards.

The Path Forward and a Pivotal Date

Looking ahead, Gerresheimer is targeting 2026 revenue of €2.3 billion to €2.4 billion, albeit with an expected weak first half. All attention, however, is fixed on March 31, 2026. Submitting the certified annual report by this deadline is critical; success could allow the company to address core aspects of the BaFin investigations. Missing it would almost certainly intensify the crisis. The company's first-quarter report is scheduled for April 16, with the Annual General Meeting set for June 3.